Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RA2708 | Tofacitinib | 0.3 | uM | 2 | MCP-1 (MCAF) | 191.0 | 50 | ||||
| RA2708 | 2 | MCP-1 (MCAF) | 230.0 | 62 | |||||||
| RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 664.0 | 58 | |
| RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 2407.0 | 57 | |
| N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 3056.0 | 62 | |
| N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 4359.0 | 67 | |
| RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 590.0 | 69 | |
| RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 1458.0 | 66 | |
| RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 7624.0 | 38 | |
| RA2159 | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 8294.0 | 57 | ||||
| N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 8648.0 | 45 | |
| N2645 | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 9065.0 | 47 | ||||
| RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 7493.0 | 46 | |
| RA2708 | TNF-a | 100 | ng/mL | 2 | MCP-1 (MCAF) | 7619.5 | 48 | ||||
| RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 124.0 | 53 | |
| RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 595.0 | 41 | |
| N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 569.0 | 53 | |
| N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 2514.0 | 59 | |
| RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 176.0 | 70 | |
| RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 944.0 | 45 | |
| RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 7152.0 | 47 | |
| RA2159 | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 7650.0 | 52 | ||||
| N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 8219.0 | 49 | |
| N2645 | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 8256.0 | 51 | ||||
| RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | MCP-1 (MCAF) | 7260.0 | 49 |